The phase three trial of revusiran that targets hepatic transthyretin (TTR) for treating cardiomyopathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis was discontinued after a median of 6.71 months due to observed mortality imbalance between revusiran and placebo cohorts. This evidence concerns the gene TTR and cardiomyopathy.